A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This clinical trial evaluates adding high-dose ascorbate (vitamin C) to a standard therapy
for non-small cell lung cancer. The standard therapy is radiation therapy combined with
carboplatin and paclitaxel (types of chemotherapy). All subjects will receive high-dose
ascorbate in addition to the standard therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Joseph J. Cullen, MD, FACS University of Iowa
Collaborators:
Holden Comprehensive Cancer Center National Cancer Institute (NCI) National Institutes of Health (NIH)